Comparative Pharmacology
Head-to-head clinical analysis: IDVYNSO versus NOVANTRONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IDVYNSO versus NOVANTRONE.
IDVYNSO vs NOVANTRONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
IDVYNSO is a selective dopamine D3 receptor antagonist, which modulates dopaminergic neurotransmission in the mesolimbic pathway.
Mitoxantrone is a synthetic anthracenedione derivative that intercalates with DNA and inhibits topoisomerase II, leading to DNA strand breaks and inhibition of DNA and RNA synthesis. It also disrupts DNA repair and replication, and has immunosuppressive effects through inhibition of B cell, T cell, and macrophage function.
5 mg/kg IV once daily for 14 days; then 2.5 mg/kg IV once daily for 14 days.
12 mg/m2 IV over 5-15 minutes once daily on days 1-3 of a 28-day cycle, or as a single dose of 12-14 mg/m2 IV every 21 days. For acute nonlymphocytic leukemia, 12 mg/m2 IV daily for 3 days with cytarabine.
None Documented
None Documented
Terminal elimination half-life is 12–18 hours, supporting twice-daily dosing in patients with normal renal function.
Terminal elimination half-life: 23-215 hours (mean ~37 hours). The long half-life reflects extensive tissue distribution and slow elimination, allowing weekly dosing.
Renal excretion of unchanged drug accounts for approximately 60% of elimination; biliary/fecal excretion accounts for 30%, with the remainder metabolized.
Primarily hepatic (biliary/fecal) elimination: ~25% as unchanged drug and metabolites in feces over 5 days; renal excretion accounts for ~11% (6-11%) as unchanged drug. Less than 10% excreted unchanged in urine.
Category C
Category C
Antineoplastic Agent
Antineoplastic Agent